Recombinant human beta-glucuronidase (rhGUS) ( DrugBank: Recombinant human beta-glucuronidase )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 4 |
19. ライソゾーム病
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2051190085 | 06/01/2020 | 19/12/2019 | A long-term study of beta-glucuronidase enzyme replacement therapy for Sly disease | A long-term, open label, extension study to assess the efficacy and safety of beta-glucuronidase enzyme replacement therapy in Japanese patients with mucopolysaccharidosis type VII, Sly disease | Mucopolysaccharidosis type VII Mucopolysaccharidosis VII, Sly syndrome, beta-glucuronidase, vestronidase alfa;D016538 | Investigational drug: Vestronidase alfa [Recombinant human beta-glucuronidase (rhGUS)], 4 mg/kg, IV, QOW | Hamazaki Takashi | NULL | Recruiting | Not applicable | Not applicable | Both | 4 | Phase 3 | Japan |
| 2 | EUCTR2015-001875-32-PT (EUCTR) | 18/04/2016 | 19/01/2016 | A long-term safety and efficacy study in MPS 7 patients receiving enzyme (UX003) replacement by intravenous injection | A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects with MPS 7 | Mucopolysaccharidosis type 7 ( MPS 7, Sly syndrome);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Recombinant human beta-glucuronidase (rhGUS) Product Code: UX003 INN or Proposed INN: pending Other descriptive name: RECOMBINANT HUMAN BETA GLUCURONIDASE; RHGUS | Ultragenyx Pharmaceutical Inc. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Portugal;Mexico;Brazil | ||
| 3 | NCT02432144 (ClinicalTrials.gov) | November 10, 2015 | 22/4/2015 | A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) | A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7 | Sly Syndrome;MPS VII;Mucopolysaccharidosis;Mucopolysaccharidosis VII | Drug: UX003 | Ultragenyx Pharmaceutical Inc | NULL | Completed | 5 Years | N/A | All | 12 | Phase 3 | United States;Brazil;Mexico;Portugal |
| 4 | NCT02418455 (ClinicalTrials.gov) | July 21, 2015 | 12/4/2015 | Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age | An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old | Sly Syndrome;MPS VII;Mucopolysaccharidosis;Mucopolysaccharidosis VII | Drug: UX003 | Ultragenyx Pharmaceutical Inc | NULL | Completed | N/A | 5 Years | All | 8 | Phase 2 | United States;Portugal;Spain |